The clinical study for effectiveness and safeness of levetiracetam combination therapy for symptomatic seizure

The clinical study for effectiveness and safeness of levetiracetam combination therapy for symptomatic seizure - The effectiveness of levetiracetam combination therapy

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000006186

Enrollment

Registered

2011-09-01

Start date

2011-07-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

symptomatic intractable epilepsy

Interventions

Medication of levetiracetum

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: The intended patients which have symptomatic intractable epilepsy due to brain tumor,apoplexy and brain trauma. they have already taken other existing other anti-epileptic drugs.

Exclusion criteria

Exclusion criteria: The pateints which can not be estimated the attack frequency during study peroid and with serious liver dysfunction, renal dysfunaction, severe brain vascular disease, brain tumor or metal disfunction. A women with pregnacy or a possibility of pregnacy

Design outcomes

Primary

Measure	Time frame
disppearace rate of attack reduction rate of attack frequency	—

Secondary

Measure	Time frame
QOLIE-31	—

Countries

Japan

Contacts

Public ContactKawataki Tomoyuki

Faculity of Meidison, Yamanashi Univiersity Department of Neurosurgery

kawataki@yamanashi.ac.jp055-243-6786

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026